LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

Home・Aandelen Lijst・Organon & Co

Search

Organon & Co

Gesloten

SectorGezondheidszorg

13.4 0.83

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

13.29

Max

13.43

Belangrijke statistieken
By Trading Economics
Inkomsten	351M 146M
Verkoop	-47M 1.5B
K/W Sectorgemiddelde	14.106 49.8
EPS	0.71
Dividendrendement	0.6
Winstmarge	10
Werknemers	10,000
EBITDA	286M 351M

Aanbevelingen
By TipRanks
Aanbevelingen	Sell
12 Maanden Prognose	-15.54% downside

Dividenden
By Dow Jones
Dividendrendement Sectorgemiddelde	0.60% 2.25%
Volgende Winsten	4 aug 2026
Volgende dividenddatum	11 jun 2026
Volgende Ex Dividend datum	11 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	26M 3.5B
Vorige openingsprijs	12.57
Vorige sluitingsprijs	13.4

Nieuwssentiment

By Acuity

69%

31%

317 / 347 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

8.53 / 9.18 Steun & Weerstand

Organon & Co Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

27 apr 2026, 06:09 UTC

Acquisities, Fusies, Overnames

India's Sun Pharma to Buy U.S. Healthcare Company Organon in $11.75 Billion Deal -- 2nd Update

27 apr 2026, 02:33 UTC

Acquisities, Fusies, Overnames

India's Sun Pharma to Buy U.S. Healthcare Firm Organon in $11.75 Billion Deal - Update

27 apr 2026, 01:04 UTC

Acquisities, Fusies, Overnames

Sun Pharmaceutical to Acquire Organon Valued at $11.75 Billion

7 nov 2025, 14:41 UTC

Acquisities, Fusies, Overnames

Laborie to Buy Specialist Medical Device For Up To $465 Million From Organon

27 apr 2026, 18:07 UTC

Acquisities, Fusies, Overnames

Organon Rides the Pharma M&A Wave With Sun Takeover. The Stock Sizzles. -- Barrons.com

27 apr 2026, 15:14 UTC

Acquisities, Fusies, Overnames

Sun Pharma to Buy U.S. Healthcare Firm Organon in $11.75 Billion Deal -- Update

27 apr 2026, 14:56 UTC

Acquisities, Fusies, Overnames

Organon Stock Soars. It's Riding the Pharma M&A Wave as Sun Seals Takeover. -- Barrons.com

27 apr 2026, 13:58 UTC

Acquisities, Fusies, Overnames

Organon Stock Soars. It's Riding the Pharma M&A Wave as Sun Seals Takeover. -- Barrons.com

27 apr 2026, 13:38 UTC

Populaire aandelen

Stocks to Watch Monday: Frontier, Domino's Pizza, Qualcomm -- WSJ

27 apr 2026, 12:18 UTC

Acquisities, Fusies, Overnames

Another Pharma Takeover Shows the Sector Is Hot. Organon Stock Rides the M&A Wave. -- Barrons.com

27 apr 2026, 09:22 UTC

Acquisities, Fusies, Overnames

Organon Stock Jumps After Sun Seals Takeover. Why Pharma M&A Is a Hot Play. -- Barrons.com

27 apr 2026, 00:38 UTC

Acquisities, Fusies, Overnames

Sun Pharmaceutical to Acquire Organon Shares for $14.00 Each in an All Cash Deal

27 apr 2026, 00:38 UTC

Acquisities, Fusies, Overnames

Sun Pharmaceutical to Acquire Organon & Co. at an Enterprise Value of $11.75B

24 apr 2026, 20:51 UTC

Acquisities, Fusies, Overnames

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 apr 2026, 20:39 UTC

Acquisities, Fusies, Overnames

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 apr 2026, 19:25 UTC

Acquisities, Fusies, Overnames

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 apr 2026, 17:09 UTC

Acquisities, Fusies, Overnames

Organon Stock Surges on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

10 apr 2026, 20:10 UTC

Acquisities, Fusies, Overnames

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

10 apr 2026, 14:39 UTC

Acquisities, Fusies, Overnames

Update: This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

10 apr 2026, 14:01 UTC

Acquisities, Fusies, Overnames

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

10 apr 2026, 09:23 UTC

Populaire aandelen

Stocks to Watch Friday: Lumentum, Coherent, Porsche -- WSJ

Peer Vergelijking

Prijswijziging

Organon & Co Prognose

Koersdoel

By TipRanks

-15.54% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 11.2 USD -15.54%

Hoogste 14 USD

Laagste 8 USD

Gebaseerd op 7 Wall Street-analisten die 12-maands prijsdoelen bieden voor Organon & Co - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Sell

7 ratings

0

Buy

4

Hold

3

Sell

Gebaseerd op 7 analisten die aandelenratings hebben gegeven aan Organon & Co - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

8.53 / 9.18Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bearish.

There are no events.

Sentiment

By Acuity

317 / 347 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Organon & Co

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.

Andere aandelen uit de sector

LLY

Eli Lilly and Co.

986

JNJ

Johnson and Johnson

224.47

ABBV

AbbVie Inc

204.99

UNH

UnitedHealth Group Inc

366.96

AZN

AstraZeneca PLC

184.44

Live chat